MARIPOSA-2

NCT04988295 📎

Regimen

Experimental
amivantamab+chemo ± lazertinib
Control
chemo alone

Population

Post-osimertinib EGFR-mut NSCLC

Key finding

ami+chemo vs chemo PFS HR 0.48 (0.36-0.64); ami+laz+chemo HR 0.44 (0.35-0.56); established ami-based SoC after osi

Source: PMID 37879444

Timeline

  • Enrollment start: 2021-11-17 📎

Guideline citations

  • NCCN NSCLC Version 5.2026 (p.112)
  • CSCO NSCLC 2025 ⚠️ OCR source